Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA.

Clin Cancer Res · 2023 · PMC9811154 · PMID 36318705

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

Nominally significant improvements in rPFS, ORR, and OS, were reported for the olaparib group compared with the control treatment group for the Cohort A ctDNA subgroup; these improvements were comparable with those that have previously been reported for the 245 patients from the overall Cohort A ITT population with BRCA/ ATM alterations identified by prospective tumor-based NGS testing ( 4, 5 ).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.